MAD2 activates IGF1R/PI3K/AKT pathway and promotes cholangiocarcinoma progression by interfering USP44/LIMA1 complex.
Jiang W, Yang X, Shi K, Zhang Y, Shi X, Wang J, Wang Y, Chenyan A, Shan J, Wang Y, Chang J, Chen R, Zhou T, Zhu Y, Yu Y, Li C, Li X.
Jiang W, et al. Among authors: yu y.
Oncogene. 2023 Nov;42(45):3344-3357. doi: 10.1038/s41388-023-02849-6. Epub 2023 Sep 26.
Oncogene. 2023.
PMID: 37752233